Xinyue Bio closes multi-million RMB Series A+ round with follow-on from XtalPi (2228.HK). This latest funding, secured within six months of XtalPi's initial investment, underscores strong investor confidence.

The funds will drive the R&D of Xinyue Bio's "DEL+AI" platform and accelerate the clinical development of its pipeline, aiming to boost efficiency and success rates in early drug discovery.

Synergy in Action: Building a New Engine for Drug R&D

Xinyue Bio specializes in the advanced development and application of DNA-Encoded Library (DEL) technology, dedicated to empowering and advancing innovative drug discovery. The company's proprietary DEL live-cell screening platform enables effective screening of membrane proteins that are difficult to express and purify. This not only expands the range of druggable targets accessible to DEL technology but also represents a screening approach that more closely mimics physiological conditions.

As a pioneer in AI-driven drug discovery, XtalPi leverages a high-precision drug design platform that integrates quantum physics, AI algorithms, and automated robotic experimentation. XtalPi possesses the capability to explore ultra-large chemical spaces and rapidly optimize molecules, leading the transformation of next-generation intelligent drug discovery.

Through this strategic collaboration, the two parties will continue to deeply synergize across key R&D stages, including target discovery, molecular design optimization, and preclinical research. By integrating "high-throughput DEL screening" with "AI-powered intelligent analysis and optimization," the partnership aims to break through the bottlenecks of traditional drug development—characterized by long cycles, high costs, and low success rates—ushering in a new era of more efficient and precise drug discovery.

Future-Ready: Co-Creating the Blueprint for Biotech

The deep integration of AI and biotechnology is currently ushering the global pharmaceutical industry into a new era of intelligent R&D. The collaboration between Xinyue Bio and XtalPi represents not only a synergy of technological innovation but also a high alignment of industrial resources and strategic vision. Looking ahead, the two parties will continue to explore the deep application of DEL and AI across a broader range of disease areas and pipeline development, empowering Chinese innovative pharmaceutical companies to gain greater discourse power on the global stage.

About XtalPi

XtalPi Holdings Limited (Stock Short Name: XTALPI-P, Stock Code: 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform empowered by artificial intelligence and driven by robotics, underpinned by quantum physics.

The Company combines first-principles calculations based on quantum physics, artificial intelligence, high-performance cloud computing, and scalable, standardized robotic automation. XtalPi provides drug discovery and materials science R&D solutions and services to global and domestic companies across industries such as pharmaceuticals and materials science (including agricultural technology, energy, novel chemicals, and cosmetics).

About Xinyue Bio

Shenzhen Xinyue Biotechnology Co., Ltd. (hereinafter referred to as "Xinyue Bio") is a clinical-stage innovative drug R&D company incubated and controlled by the Guangdong Innovative Center for Small Molecule Drugs. Founded in April 2021, the company builds multiple 0-to-1 drug discovery technology platforms based on DNA-Encoded Library (DEL) technology and possesses a compound library of over 100 billion physical molecules. Xinyue Bio's proprietary DEL live-cell screening technology can effectively screen membrane proteins that are difficult to express and purify, significantly expanding the range of targetable proteins and improving the hit rate of new drug discovery. Guided by the mission to "Empower drug development with distinctive technologies and create high-quality medicines affordable to the public," Xinyue Bio is committed to becoming an internationally leading and distinctive biopharmaceutical company.